Floatz logo

Reboxetine

Abdominal Pain

Hospital Universitari Vall d'Hebron Research InstituteSmall moleculePhase 4 / ApprovedDormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Abdominal Pain cohort.

Asset / SponsorPhaseRating
Cipralex
Hospital Universitari Vall d'Hebron Research Institute
Phase 4BB
TANNIC ACID
Hospital Infantil Cândido Fontoura
Phase 3BB
DESIPRAMINE
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3BB
LIDOCAINE
Hospital Infantil Cândido Fontoura
Phase 3BB
Ketorolac Tromethamine
Hamilton Health Sciences Corporation
Phase 3B

View all 15 →

Same molecule, other indications

Reboxetine is also rated in:

PainDormant
B
Indicative ·
59 / 100
View asset →
major depressive disorderDormant
B
Indicative ·
59 / 100
View asset →
stroke disorderDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →